Skip to main content
OpenTrials
Completed

NCT Number: NCT02814201

Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Chorea Cognition Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dementia Dyskinesias Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Huntington Disease Mental Disorders Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens

Amiens, 80054, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Agreeing to participate in the study
  • French mother tongue
  • MMSE > 20/30
  • Specific to the MP and MH:
  • Parkinson's disease:
  • defined by the criteria of the UKPDSBB
  • stage 1 , 2 or 3 Hoehn and Yahr (ON)
  • age of onset of the disease known
  • brain MRI performed during follow-up
  • Huntington disease :
  • genetically defined (CAG > 35)
  • weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)
  • Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

Exclusion criteria

  • Illiteracy, writing or reading difficulties
  • Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions
  • Visual hallucinations
  • Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not)
  • Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment.
  • Psychiatric disorders depression unless treated (stable treatment for 1 month)
  • Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)
  • Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters.
  • Inability to stand without technical assistance for 30 seconds.

Treatment and study plan

SRT

Behavioral

simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Primary outcomes

  1. SRT

    Time frame: Day 0

    simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: ERAMPPCI

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Jun 27, 2016
Registry last updated
Dec 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.